Literature DB >> 11861329

Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.

Andrew J Batey1, Susan J Coker.   

Abstract

1. This study was designed to compare the proarrhythmic activity of the antimalarial drug, halofantrine and the antihistamine, terfenadine, with that of clofilium a K(+) channel blocking drug that can induce torsade de pointes. 2. Experiments were performed in pentobarbitone-anaesthetized, open-chest rabbits. Each rabbit received intermittent, rising dose i.v. infusions of the alpha-adrenoceptor agonist phenylephrine. During these infusions rabbits also received increasing i.v. doses of clofilium (20, 60 and 200 nmol kg(-1) min(-1)), terfenadine (75, 250 and 750 nmol kg(-1) min(-1)), halofantrine (6, 20 and 60 micromol kg(-1)) or vehicle. 3. Clofilium and halofantrine caused dose-dependent increases in the rate-corrected QT interval (QTc), whereas terfenadine prolonged PR and QRS intervals rather than prolonging cardiac repolarization. Progressive bradycardia occurred in all groups. After administration of the highest dose of each drug halofantrine caused a modest decrease in blood pressure, but terfenadine had profound hypotensive effects resulting in death of most rabbits. 4. The total number of ventricular premature beats was highest in the clofilium group. Torsade de pointes occurred in 6 out of 8 clofilium-treated rabbits and 4 out of 6 of those which received halofantrine, but was not seen in any of the seven terfenadine-treated rabbits. 5. These results show that, like clofilium, halofantrine can cause torsade de pointes in a modified anaesthetized rabbit model whereas the primary adverse effect of terfenadine was cardiac contractile failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861329      PMCID: PMC1573214          DOI: 10.1038/sj.bjp.0704550

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine.

Authors:  I D Lightbown; J P Lambert; G Edwards; S J Coker
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Functional consequences of the arrhythmogenic G306R KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes.

Authors:  R A Li; J Miake; U C Hoppe; D C Johns; E Marbán; H B Nuss
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

3.  Prolonged QT interval with halofantrine.

Authors:  A Castot; P Rapoport; P Le Coz
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

4.  Prolonged QT interval with halofantrine.

Authors:  E Monlun; O Pillet; J F Cochard; J C Favarel Garrigues; M le Bras
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

5.  Cardiac effects of antimalarial treatment with halofantrine.

Authors:  F Nosten; F O ter Kuile; C Luxemburger; C Woodrow; D E Kyle; T Chongsuphajaisiddhi; N J White
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

6.  Selective inhibition of potassium currents in rat ventricle by clofilium and its tertiary homolog.

Authors:  N A Castle
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030

7.  QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions.

Authors:  L Carlsson; O Almgren; G Duker
Journal:  J Cardiovasc Pharmacol       Date:  1990-08       Impact factor: 3.105

8.  Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine.

Authors:  C M Pratt; R P Hertz; B E Ellis; S P Crowell; W Louv; L Moyé
Journal:  Am J Cardiol       Date:  1994-02-15       Impact factor: 2.778

9.  Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.

Authors:  L V Buchanan; G Kabell; M N Brunden; J K Gibson
Journal:  J Cardiovasc Pharmacol       Date:  1993-10       Impact factor: 3.105

10.  Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.

Authors:  L Carlsson; C Abrahamsson; B Andersson; G Duker; G Schiller-Linhardt
Journal:  Cardiovasc Res       Date:  1993-12       Impact factor: 10.787

View more
  19 in total

1.  The electro-mechanical window in anaesthetized guinea pigs: a new marker in screening for Torsade de Pointes risk.

Authors:  P-J Guns; D M Johnson; J Van Op den Bosch; E Weltens; J Lissens
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

Authors:  Hua Rong Lu; An N Hermans; David J Gallacher
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in Ischemic Stroke.

Authors:  Chung-Yang Yeh; Ashlyn M Bulas; Aubin Moutal; Jami L Saloman; Karen A Hartnett; Charles T Anderson; Thanos Tzounopoulos; Dandan Sun; Rajesh Khanna; Elias Aizenman
Journal:  J Neurosci       Date:  2017-05-08       Impact factor: 6.167

5.  Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model.

Authors:  A Farkas; J Dempster; S J Coker
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

6.  Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.

Authors:  Chengzong Han; Steven M Pogwizd; Cheryl R Killingsworth; Zhaoye Zhou; Bin He
Journal:  Heart Rhythm       Date:  2013-06-14       Impact factor: 6.343

7.  Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits.

Authors:  D Vincze; A S Farkas; L Rudas; P Makra; N Csík; I Leprán; T Forster; M Csanády; J G Papp; A Varró; A Farkas
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

8.  Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation.

Authors:  G Michael; J Dempster; K A Kane; S J Coker
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

9.  The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts.

Authors:  Attila S Farkas; Péter Makra; Norbert Csík; Szabolcs Orosz; Michael J Shattock; Ferenc Fülöp; Tamás Forster; Miklós Csanády; Julius Gy Papp; András Varró; András Farkas
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

10.  Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs.

Authors:  G Michael; K A Kane; S J Coker
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.